Tom 16, Nr 2 (2020)
Artykuł przeglądowy
Opublikowany online: 2020-06-30
Wyświetlenia strony
4060
Wyświetlenia/pobrania artykułu
183
Postępowanie w chorobach pierwotnie mięśniowych w okresie pandemii COVID-19
Pol. Przegl. Neurol 2020;16(2):80-83.
Streszczenie
Pandemia COVID-19 może w istotny sposób wpływać na opiekę nad pacjentami z pierwotnymi chorobami mięśni. W pracy: 1) omówiono potencjalny wpływ SARS-CoV-2 na komórkę mięśniową, 2) przedstawiono zalecenia dotyczące zmniejszenia ryzyka infekcji COVID-19 i ewentualnego leczenia SARS-CoV-2 u pacjentów z wcześniej rozpoznaną chorobą pierwotnie mięśniową, 3) wskazano kierunki kontynuowania terapii immunosupresyjnej i immunomodulacyjnej, ACE-I oraz sartanami u chorych z miopatiami, 4) omówiono potencjalny wpływ leków przeciwwirusowych na nerwy obwodowe i komórkę mięśniową.
Słowa kluczowe: COVID-19miopatia zapalnachoroby pierwotnie mięśnioweleczenie przeciwwirusowe SARS-CoV-2
Referencje
- Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020.
- Avula A, Nalleballe K, Narula N, et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020.
- Manji H, Carr A, Brownlee W, et al. Neurology in the time of COVID-19. J Neurol Neurosurg Psychiatry. 2020; 91(6): 568–570.
- Needham EJ, Chou SHY, Coles AJ, et al. Neurological implications of COVID-19 infections. Neurocrit Care. 2020.
- Guidon AC, Amato A. COVID-19 and neuromuscular disorders. Neurology. 2020: 10.1212/WNL.0000000000009566.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
- Wang D, Hu Bo, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069.
- Leung TW, Wong K, Hui AC, et al. Myopathic changes associated with severe acute respiratory syndrome. Arch Neurol. 2005; 62(7): 1113–1117.
- Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis. 2004; 10(5): 818–824.
- Fan CK, Yieh KM, Peng MY, et al. Clinical and laboratory features in the early stage of severe acute respiratory syndrome. J Microbiol Immunol Infect. 2006; 39(1): 45–53.
- Chen LL, Hsu CW, Tian YC, et al. Rhabdomyolysis associated with acute renal failure in patients with severe acute respiratory syndrome. Int J Clin Pract. 2005; 59(10): 1162–1166.
- Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor ofWuhan 2019-nCov. bioRxiv. 2020.
- Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathology. 2004; 203(2): 631–637.
- Veerapandiyan A, Wagner K, Apkon S, et al. The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID‐19 pandemic. Muscle Nerve. 2020.
- Kinnett K, Noritz G. The PJ Nicholoff steroid protocol for Duchenne and Becker muscular dystrophy and adrenal suppression. PLoS Curr. 2017.
- Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020.
- Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020; 64(5).
- Cao B, Wang Y, Wen D. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382(382(19): 1787–1799.
- Cheng CH, Miller C, Lowe C, et al. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002; 59(8): 728–730.
- Ming JM, Gill M. Case report: drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care and STDs. 2003; 17(5): 207–210.
- Mulangu S, Dodd L, Davey R, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019; 381(24): 2293–2303.
- Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; 57: 279–283.
- Guastalegname M, Vallone A. Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin Infect Dis . 2020.
- Eadie MJ, Ferrier TM. Chloroquine myopathy. J Neurol Neurosurg Psychiatry . 1966; 29(4): 331–337.
- Mastaglia FL, Papadimitriou JM, Dawkins RL, et al. Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. J Neurol Sci. 1977; 34(3): 315–328.
- Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2012; 2(1): 77–83.
